Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Procrit Grows In Q1 Despite Challenges For ESAs

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. sales of the erythropoiesis-stimulating agent grew 1 percent in Q1 on strong sales in the hospital and retail market.

You may also be interested in...



Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan

After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.

EPO Aggressive Dosing May Be Curtailed By New Black Box Warning

Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.

Amgen Bundling Discounts Will Continue As J&J Case Heads To Trial

Court denies injunction sought by J&J to stop Amgen discounts based on amount of anemia products purchased.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel